SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 15, 2011 08:16 ET

Mistral Ventures and Cannabis Sciences - Unique Routes to Success

The Paragon Report Provides Equity Research on Mistral Ventures & Cannabis Sciences

NEW YORK, NY--(Marketwire - Nov 15, 2011) - While traditional biotech companies typically have to struggle through several years, and millions of dollars, before possibly reaching FDA approval, natural supplements can have a far easier time reaching the market. In recent years the supplement market has skyrocketed, while the traditional synthetic biotech industry has battled with a stricter FDA approval system. The Paragon Report examines investing opportunities in the Healthcare Sector and provides equity research on Mistral Ventures, Inc. (PINKSHEETS: MILV) and Cannabis Sciences, Inc. (OTCBB: CBIS). Access to the full company reports can be found at:

Some lawmakers in Washington have been arguing that the FDA's tougher safety stance has slowed down the pace of drug approvals and is hurting the pharmaceutical and biotech industry. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.

Janet Woodcock, the head of the FDA's drug division, defended the FDA's role, saying challenges being faced by the biotech and pharmaceutical industry are related to high failure rates of drugs in the development process rather than FDA regulations.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the Healthcare Sector register with us free at and get exclusive access to our numerous stock reports and industry newsletters

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures, says that its line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994. Last week the company announced that it is finalizing arrangements to commence production of its Breathing Relief Formula. Robert deZanger, CEO of Nature's Bioceuticals went as far as to say the company "anticipate sales in excess of $10,000,000.00 the first year and then expanding and exponentially thereafter."

Cannabis Science Inc. is a development stage company engaged in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. It primarily focuses on developing medications to treat autism, blood pressure, cancer and cancer side effects, HIV, and other illnesses, including general health maintenance.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at